Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Auto-immuunziekte geen contra-indicatie voor PD-(L)1-remmer
jul 2022 | Immuuntherapie